Navigation Links
New Drug Promising Against Tough-to-Treat Kidney Cancer
Date:10/30/2007

Axitinib produced good responses in almost half of patients, study found

TUESDAY, Oct. 30 (HealthDay News) -- An experimental drug called axitinib shows promise for treating people with what's known as cytokine-refractory metastatic kidney cancer -- a group of patients who typically have a poor response to drug treatment.

Axitinib is a selective inhibitor of cancer-linked proteins known as vascular endothelial growth factor receptors 1, 2 and 3.

As reported in the November issue of The Lancet Oncology, the phase II study of 52 patients treated with the drug found that 23 patients had complete or partial responses (some of which were long lasting), and 12 of these patients progressed during the study, with a duration of response ranging from four months to 26 months.

The French researchers also found that 22 patients showed stable disease for longer than eight weeks, including 13 patients with stable disease for 24 weeks or longer.

Four patients had early disease progression, and 30 patients had high blood pressure related to the treatment. In general, side effects were manageable and controlled by dose modification or supportive care, the researchers said.

"The objective response and time to progression in our study suggest that axitinib might be a promising drug in the treatment of patients with metastatic renal-cell cancer, although a randomized controlled trial is needed to confirm this finding," study author Olivier Rixe, a professor in the department of medical oncology at the University of Paris, said in a prepared statement.

These findings "suggest that a drug such as axitinib has promise as a second-line treatment in cytokine-refractory metastatic renal-cell carcinoma and might have potential as first-line treatment or in combination with other agents," Dr. W. Marston Linehan of the U.S. National Cancer Institute, wrote in an accompanying comment.

More information

The U.S. National Cancer Institute has more about kidney cancer.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, Oct. 30, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. Promising Treatment for Diabetes
4. A promising treatment for wart removal
5. Hepatitis shots is promising
6. Life after Bypass not so Promising for Women.
7. Promising cure for West Nile Virus
8. Deadly Diarrhoea Vaccine – Trail Results Promising
9. Novartis MS Drug Shows Promising Results
10. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
11. Research Ethics Requirements Compromising Quality of Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
Breaking Medicine Technology: